Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study of Abicipar Pegol in Patients With Diabetic Macular Edema

Next Previous
Trial Profile

A Study of Abicipar Pegol in Patients With Diabetic Macular Edema

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 Jan 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abicipar pegol (Primary) ; Ranibizumab
  • Indications Diabetic macular oedema
  • Focus Therapeutic Use
  • Sponsors Allergan

Most Recent Events

  • 27 Oct 2016 Data from this trial were presented at the 2016 American Academy of Ophthalmology Annual Meeting, according to an Allergan media release.
  • 10 Oct 2016 According to Allergan media release, new data will be presented at the 2016 American Academy of Ophthalmology Annual Meeting in Chicago.
  • 13 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top